NAICS 541714: Research and Development in Biotechnology
This U.S. industry comprises establishments primarily engaged in conducting biotechnology (except nanobiotechnology) research and experimental development.  Biotechnology (except nanobiotechnology) research and experimental development involves the study of the use of microorganisms and cellular and biomolecular processes to develop or alter living or non-living materials.  This research and development in biotechnology (except nanobiotechnology) may result in development of new biotechnology (except nanobiotechnology) processes or in prototypes of new or genetically-altered products that may be reproduced, utilized, or implemented by various industries.

Illustrative Examples:

Cloning research and experimental development laboratories 
DNA technologies (e.g., microarrays) research and experimental development laboratories
Nucleic acid chemistry research and experimental development laboratories
Protein engineering research and experimental development laboratories
Recombinant DNA research and experimental development laboratories 

ExioML sector: Research and development services (73)
Region: US | Year: 2022
Sector value added: 101689.895384 M EUR | Employment: 9284.95382206 thousand persons
Sector GHG emissions: 1501417868.95 kg CO2 eq | Energy carrier net total: 142153.6007 TJ | Carbon intensity: 0.014764671192554249

Company: Vir Biotechnology Inc
Vir Biotechnology, Inc. operates as a clinical-stage immunology company. The Company develops and commercializes therapeutics and medicines for the treatments and preventions for viral and bacterial diseases. Vir Biotechnology serves customers in the State of California.